BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23225412)

  • 21. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
    Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
    Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571.
    Wozniak K; Czechowska A; Blasiak J
    Chem Biol Interact; 2004 Apr; 147(3):309-18. PubMed ID: 15135086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM; van der Zee AG; van den Heuvel FA; Timmer T; de Vries EG; de Jong S
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
    Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
    Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines.
    De Santi M; Galluzzi L; Duranti A; Magnani M; Brandi G
    Anticancer Res; 2013 May; 33(5):1867-72. PubMed ID: 23645732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
    Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
    McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
    Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved chemosensitivity in cervical cancer to cisplatin: synergistic activity of mahanine through STAT3 inhibition.
    Das R; Bhattacharya K; Samanta SK; Pal BC; Mandal C
    Cancer Lett; 2014 Aug; 351(1):81-90. PubMed ID: 24831030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
    Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
    Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M; Hashimoto K; Shimada J; Sakagami H
    Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation.
    Pariente R; Pariente JA; Rodríguez AB; Espino J
    J Pineal Res; 2016 Jan; 60(1):55-64. PubMed ID: 26462739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic effect of paeonol and cisplatin on oesophageal cancer cell lines.
    Wan XA; Sun GP; Wang H; Xu SP; Wang ZG; Liu SH
    Dig Liver Dis; 2008 Jul; 40(7):531-9. PubMed ID: 18339596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells.
    Lee JY; Shin JY; Kim HS; Heo JI; Kho YJ; Kang HJ; Park SH; Lee JY
    Oncol Rep; 2012 Jan; 27(1):87-93. PubMed ID: 21922150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
    Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
    Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.